{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:04:31Z","timestamp":1793052271493,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bcp.2019.113731","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T19:39:36Z","timestamp":1574797176000},"page":"113731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Stereoselective cell uptake of adrenergic agonists and antagonists by organic cation transporters"],"prefix":"10.1016","volume":"171","author":[{"given":"Ole","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Rafehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mladen V.","family":"Tzvetkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Brockm\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.bcp.2019.113731_b0005","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1021\/jm400966v","article-title":"Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2","volume":"56","author":"Hendrickx","year":"2013","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2019.113731_b0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/pupt.2001.0327","article-title":"Biological actions of formoterol isomers","volume":"15","author":"Handley","year":"2002","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2019.113731_b0015","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1067\/mai.2001.119152","article-title":"The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients","volume":"108","author":"L\u00f6tvall","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.bcp.2019.113731_b0020","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2174\/138920011795713724","article-title":"Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities","volume":"12","author":"Niwa","year":"2011","journal-title":"Curr. Drug Metab."},{"issue":"2","key":"10.1016\/j.bcp.2019.113731_b0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/chir.530010205","article-title":"Stereoselective sulfation of terbutaline by the rat liver cytosol: evaluation of experimental approaches","volume":"1","author":"Walle","year":"1989","journal-title":"Chirality"},{"issue":"4","key":"10.1016\/j.bcp.2019.113731_b0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/1520-6017(200104)90:4<397::AID-JPS1000>3.0.CO;2-D","article-title":"Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters","volume":"90","author":"Dresser","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2019.113731_b0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13073-015-0172-0","article-title":"Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1","author":"Seitz","year":"2015","journal-title":"Genome Med 7(1)"},{"issue":"3","key":"10.1016\/j.bcp.2019.113731_b0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/03602532.2014.887094","article-title":"Stereoselectivity of chiral drug transport: a focus on enantiomer-transporter interaction","volume":"46","author":"Zhou","year":"2014","journal-title":"Drug Metab. Rev."},{"issue":"10","key":"10.1016\/j.bcp.2019.113731_b0045","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.bcp.2012.01.032","article-title":"The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1","volume":"83","author":"Saadatmand","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2019.113731_b0050","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1515\/hsz-2016-0236","article-title":"Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families","volume":"398","author":"Chen","year":"2017","journal-title":"Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2019.113731_b0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jchromb.2008.12.006","volume":"877","author":"Jiang","year":"2009","journal-title":"J. Chromatogr. B"},{"issue":"4","key":"10.1016\/j.bcp.2019.113731_b0060","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/(SICI)1520-636X(1997)9:4<329::AID-CHIR3>3.0.CO;2-8","article-title":"Chiral assay of atenolol present in microdialysis and plasma samples of rats using chiral CBH as stationary phase","volume":"9","author":"Fornstedt","year":"1997","journal-title":"Chirality"},{"key":"10.1016\/j.bcp.2019.113731_b0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jchromb.2013.06.020","article-title":"Development and validation of a sensitive LC-MS\/MS method for the determination of fenoterol in human plasma and urine samples","volume":"933","author":"Sanghvi","year":"2013","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"2","key":"10.1016\/j.bcp.2019.113731_b0070","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1365-2125.2000.00133.x","article-title":"Stereoselective glucuronidation of formoterol by human liver microsomes","volume":"49","author":"Zhang","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2019.113731_b0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.japna.2003.08.020","article-title":"Validation of a chiral HPLC assay for (R)-salbutamol sulfate","volume":"34","author":"Halabi","year":"2004","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"2","key":"10.1016\/j.bcp.2019.113731_b0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/mol.118.113498","article-title":"Rat organic cation transporter 1 contains three binding sites for substrate 1-methyl-4-phenylpyridinium per monomer","volume":"95","author":"Keller","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2019.113731_b0085","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1515\/hsz-2018-0191","article-title":"Multiple binding sites in organic cation transporters require sophisticated procedures to identify interactions of novel drugs","author":"Koepsell","year":"2019","journal-title":"Biol. Chem."},{"issue":"46","key":"10.1016\/j.bcp.2019.113731_b0090","doi-asserted-by":"crossref","first-page":"27633","DOI":"10.1074\/jbc.M115.668913","article-title":"Role of a hydrophobic pocket in polyamine interactions with the polyspecific organic cation transporter OCT3","volume":"290","author":"Li","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2019.113731_b0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/jpet.116.232660","article-title":"Molecular properties of drugs interacting with SLC22 transporters OAT1, OAT3, OCT1, and OCT2: A machine-learning approach","volume":"359","author":"Liu","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5 Pt 1","key":"10.1016\/j.bcp.2019.113731_b0100","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0091-6749(99)70414-8","article-title":"Enantiomers of bronchodilating beta2-adrenoceptor agonists: is there a cause for concern?","volume":"103","author":"Waldeck","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2019.113731_b0105","first-page":"185","article-title":"Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans","volume":"4","author":"Mehvar","year":"2001","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2019.113731_b0110","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/004982597239903","article-title":"Stereoselective sulphate conjugation of fenoterol by human phenolsulphotransferases","volume":"27","author":"Wilson","year":"1997","journal-title":"Xenobiotica"},{"issue":"7","key":"10.1016\/j.bcp.2019.113731_b0115","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/dta.2580","article-title":"Beta2 -adrenergic ligand racemic formoterol exhibits enantioselective disposition in blood and skeletal muscle of humans, and elicits myocellular PKA signaling at therapeutic inhaled doses","volume":"11","author":"Hostrup","year":"2019","journal-title":"Drug Test. Anal."},{"issue":"2","key":"10.1016\/j.bcp.2019.113731_b0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s002280050607","article-title":"Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer","volume":"55","author":"Lecaillon","year":"1999","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2019.113731_b0125","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/dta.2587","article-title":"Enantioselective disposition of (R, R)-formoterol, (S, S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control","volume":"11","author":"Jacobson","year":"2019","journal-title":"Drug Test. Anal."},{"issue":"3","key":"10.1016\/j.bcp.2019.113731_b0130","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1046\/j.1365-2125.2002.01641.x","article-title":"Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human","volume":"54","author":"Zhang","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2019.113731_b0135","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1345\/aph.1A248","article-title":"Stereoselective pharmacokinetics and pharmacodynamics of anti-asthma agents","volume":"36","author":"Vakily","year":"2002","journal-title":"Ann. Pharmacother."},{"issue":"10","key":"10.1016\/j.bcp.2019.113731_b0140","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/thx.52.10.849","article-title":"Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers","volume":"52","author":"Lipworth","year":"1997","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.bcp.2019.113731_b0145","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2710.2003.00483.x","article-title":"(R, S)-Salbutamol plasma concentrations in severe asthma","volume":"28","author":"Jacobson","year":"2003","journal-title":"J. Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2019.113731_b0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2125.1996.tb00156.x","article-title":"Enantioselective disposition of salbutamol in man following oral and intravenous administration","volume":"41","author":"Boulton","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2019.113731_b0155","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jchromb.2015.08.020","article-title":"Study on the determination and chiral inversion of R-salbutamol in human plasma and urine by liquid chromatography-tandem mass spectrometry","volume":"1002","author":"Zhou","year":"2015","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"12","key":"10.1016\/j.bcp.2019.113731_b0160","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1177\/009127009803801203","article-title":"Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers","volume":"38","author":"Gumbhir-Shah","year":"1998","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2019.113731_b0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003088-200140010-00003","article-title":"The pharmacokinetics of levosalbutamol: what are the clinical implications?","volume":"40","author":"Boulton","year":"2001","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.bcp.2019.113731_b0170","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2125.1993.tb04159.x","article-title":"Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity","volume":"35","author":"Walle","year":"1993","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2019.113731_b0175","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.dmpk.2016.11.006","article-title":"Evidences for salbutamol metabolism by respiratory and liver cell lines","volume":"32","author":"Nakpheng","year":"2017","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.bcp.2019.113731_b0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2125.2000.00102.x","article-title":"Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man\u2013no evidence of enantioselective lung metabolism","volume":"49","author":"Ward","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2019.113731_b0185","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF02772206","article-title":"Stereoselective metabolism of RS-albuterol in humans","volume":"14","author":"Walle","year":"1996","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2019.113731_b0190","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/dta.1645","article-title":"SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels?","volume":"7","author":"Jacobson","year":"2015","journal-title":"Drug Test. Anal."},{"issue":"1","key":"10.1016\/j.bcp.2019.113731_b0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF02772207","article-title":"Enantioselective disposition of albuterol in humans","volume":"14","author":"Boulton","year":"1996","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2019.113731_b0200","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jps.2600800405","article-title":"Pharmacokinetics of acebutolol enantiomers in humans","volume":"80","author":"Piquette-Miller","year":"1991","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2019.113731_b0205","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/j.1552-4604.1992.tb03820.x","article-title":"Effect of aging on the pharmacokinetics of acebutolol enantiomers","volume":"32","author":"Piquette-Miller","year":"1992","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2019.113731_b0210","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.2042-7158.1984.tb04370.x","article-title":"Preliminary study of the disposition in man of acebutolol and its metabolite, diacetolol, using a new stereoselective hplc method","volume":"36","author":"Sankey","year":"1984","journal-title":"J. Pharm. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2019.113731_b0215","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/jps.2600791007","article-title":"Pharmacokinetics of atenolol enantiomers in humans and rats","volume":"79","author":"Mehvar","year":"1990","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2019.113731_b0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/chir.530050104","article-title":"Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic, and radioligand binding studies","volume":"5","author":"Stoschitzky","year":"1993","journal-title":"Chirality"},{"issue":"4","key":"10.1016\/j.bcp.2019.113731_b0225","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/clpt.1989.47","article-title":"The pharmacokinetics of the enantiomers of atenolol","volume":"45","author":"Boyd","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2019.113731_b0230","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/chir.530050706","article-title":"Stereoselective HPLC bioanalysis of atenolol enantiomers in plasma: application to a comparative human pharmacokinetic study","volume":"5","author":"Egginger","year":"1993","journal-title":"Chirality"},{"issue":"8821","key":"10.1016\/j.bcp.2019.113731_b0235","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0140-6736(92)92233-6","article-title":"Stereoselective release of (S)-atenolol from adrenergic nerve endings at exercise","volume":"340","author":"Stoschitzky","year":"1992","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bcp.2019.113731_b0240","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/cpb.58.879","article-title":"Stereoselective glucuronidation of propafenone and its analogues by human recombinant UGT1A9","volume":"58","author":"Xie","year":"2010","journal-title":"Chem Pharm Bull (Tokyo)"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219304307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219304307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:11:57Z","timestamp":1757769117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219304307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":48,"alternative-id":["S0006295219304307"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113731","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereoselective cell uptake of adrenergic agonists and antagonists by organic cation transporters","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113731"}}